The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Fingolimod for the Treatment of Intracerebral Hemorrhage: A 2-Arm Proof-of-Concept Study
Abstract
IMPORTANCE: Pronounced inflammatory reactions occurring shortly after intracerebral hemorrhage (ICH) contribute to the formation and progression of perihematomal edema (PHE) and secondary brain injury. We hypothesized that modulation of brain inflammation reduces edema, thus improving clinical outcomes in patients with ICH. OBJECTIVE: To investigate whether oral administration of fingolimod, a Food and Drug Administration-approved sphingosine 1-phosphate receptor modulator for multiple sclerosis, is safe and effective in alleviating PHE and neurologic deficits in patients with ICH. DESIGN, SETTING, AND PARTICIPANTS: In this 2-arm, evaluator-blinded study, we included 23 patients with primary supratentorial ICH with hematomal volume of 5 to 30 mL. Clinical and neuroimaging feature-matched patients were treated with standard care with or without oral fingolimod. The study was conducted in Tianjin Medical University General Hospital, Tianjin, China. INTERVENTIONS: All patients received standard management alone (control participants) or combined with fingolimod (FTY720, Gilenya), 0.5 mg, orally for 3 consecutive days. Treatment was initiated within 1 hour after the baseline computed tomographic scan and no later than 72 hours after the onset of symptoms. MAIN OUTCOMES AND MEASURES: Neurologic status and hematomal and PHE volumes (Ev) and relative PHE, defined as Ev divided by hematomal volume, were monitored by clinical assessment and magnetic resonance imaging, respectively, for 3 months. RESULTS: Patients treated with fingolimod exhibited a reduction of neurologic impairment compared with control individuals, regained a Glasgow Coma Scale score of 15 by day 7 (100% vs 50%, P = .01), and had a National Institutes of Health Stroke Scale score reduction of 7.5 vs 0.5 (P < .001). Neurologic functions improved in these patients in the first week coincident with a reduction of circulating lymphocyte counts. At 3 months, a greater proportion of patients receiving fingolimod achieved full recovery of neurologic functions (modified Barthel Index score range, 95-100; 63% vs 0%; P = .001; modified Rankin Scale score range, 0-1; 63% vs 0%; P = .001), and fewer reported ICH-related lung infections. Perihematomal edema volume and rPHE were significantly smaller in fingolimod-treated patients than in control individuals (Ev at day 7, 47 mL vs 108 mL, P = .04; Ev at day 14, 55 mL vs 124 mL, P = .07; rPHE at day 7, 2.5 vs 6.4, P < .001; rPHE at day 14, 2.6 vs 7.7, P = .003, respectively). We recorded no differences between groups in the occurrence of adverse events. CONCLUSIONS AND RELEVANCE: In patients with small- to moderate-sized deep primary supratentorial ICH, administration of oral fingolimod within 72 hours of disease onset was safe, reduced PHE, attenuated neurologic deficits, and promoted recovery. The efficacy of fingolimod in preventing secondary brain injury in patients with ICH warrants further investigation in late-phase trials. TRIAL REGISTRATION: clinicaltrials.gov Identifier:NCT02002390.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
The immunology of stroke: from mechanisms to translation
Iadecola, C., & Anrather, J. (2011) · Nature Medicine · doi:10.1038/nm.2399 · Cited by 2,596
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Intracerebral haemorrhage: mechanisms of injury and therapeutic targets
Keep, R. F., Hua, Y., & Xi, G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70104-7 · Cited by 1,308
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Kappos, L., Antel, J., Comi, G., Montalban, X., O'Connor, P., Polman, C. H., Haas, T., Korn, A. A., Karlsson, G., & Radue, E. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052643 · Cited by 1,054
Prass, K., Meisel, C., Höflich, C., Braun, J., Halle, E., Wolf, T., Ruscher, K., Victorov, I. V., Priller, J., Dirnagl, U., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021098 · Cited by 925
Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy
Moalem, G., Leibowitz–Amit, R., Yoles, E., Mor, F., Cohen, I. R., & Schwartz, M. (1999) · Nature Medicine · doi:10.1038/4734 · Cited by 889
Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats
Rapalino, O., Lazarov-Spiegler, O., Agranov, E., Velan, G. J., Yoles, E., Fraidakis, M., Soloman, A., Gepstein, R., Katz, A., Belkin, M., et al. (1998) · Nature Medicine · doi:10.1038/nm0798-814 · Cited by 788
Lymphocyte Sequestration Through S1P Lyase Inhibition and Disruption of S1P Gradients
Schwab, S. R., Pereira, J. P., Matloubian, M., Xu, Y., Huang, Y., & Cyster, J. G. (2005) · Science · doi:10.1126/science.1113640 · Cited by 787
Graeber, M. B. (2010) · Science · doi:10.1126/science.1190929 · Cited by 608
Organ-specific features of natural killer cells
Shi, F.-D., Ljunggren, H.-G., La Cava, A., & Van Kaer, L. (2011) · Nature Reviews Immunology · doi:10.1038/nri3065 · Cited by 414
Self-citationMechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
Cohen, J. A., & Chun, J. (2011) · Annals of Neurology · doi:10.1002/ana.22426 · Cited by 393
Gebel, J. M., Jauch, E. C., Brott, T. G., Khoury, J., Sauerbeck, L., Salisbury, S., Spilker, J., Tomsick, T. A., Duldner, J., & Broderick, J. P. (2002) · Stroke · doi:10.1161/01.str.0000035283.34109.ea · Cited by 336
Recent advances in neurotrauma
Graham, D. I., McIntosh, T. K., Maxwell, W. L., & Nicoll, J. A. R. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.8.641 · Cited by 328
Gebel, J. M., Jauch, E. C., Brott, T. G., Khoury, J., Sauerbeck, L., Salisbury, S., Spilker, J., Tomsick, T. A., Duldner, J., & Broderick, J. P. (2002) · Stroke · doi:10.1161/01.str.0000035284.12699.84 · Cited by 255
Hao, J., Liu, R., Piao, W., Zhou, Q., Vollmer, T. L., Campagnolo, D. I., Xiang, R., La Cava, A., Van Kaer, L., & Shi, F.-D. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092749 · Cited by 213
Self-citationTuning of Natural Killer Cell Reactivity by NKp46 and Helios Calibrates T Cell Responses
Narni-Mancinelli, E., Jaeger, B. N., Bernat, C., Fenis, A., Kung, S., De Gassart, A., Mahmood, S., Gut, M., Heath, S. C., Estellé, J., et al. (2012) · Science · doi:10.1126/science.1215621 · Cited by 200
Rolland, W. B., Lekic, T., Krafft, P. R., Hasegawa, Y., Altay, O., Hartman, R., Ostrowski, R., Manaenko, A., Tang, J., & Zhang, J. H. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.12.009 · Cited by 200
Perihematomal Edema in Primary Intracerebral Hemorrhage Is Plasma Derived
Butcher, K. S., Baird, T., MacGregor, L., Desmond, P., Tress, B., & Davis, S. (2004) · Stroke · doi:10.1161/01.str.0000131807.54742.1a · Cited by 198
Qureshi, A. I., Ali, Z., Suri, M. F. K., Shuaib, A., Baker, G., Todd, K., Guterman, L. R., & Hopkins, L. N. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000063047.63862.99 · Cited by 184
Fingolimod is a potential novel therapy for multiple sclerosis
Aktas, O., Küry, P., Kieseier, B., & Hartung, H.-P. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.76 · Cited by 167
Intracerebral Hemorrhage-induced Neuronal Death
Gong, C., Boulis, N., Qian, J., Turner, D. E., Hoff, J. T., & Keep, R. F. (2001) · Neurosurgery · doi:10.1097/00006123-200104000-00037 · Cited by 159
Neuroimmunological Blood Brain Barrier Opening in Experimental Cerebral Malaria
Nacer, A., Movilă, A., Baer, K., Mikolajczak, S. A., Kappe, S. H. I., & Frevert, U. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002982 · Cited by 149
Hua, Y., Wu, J., Keep, R. F., Nakamura, T., Hoff, J. T., & Xi, G. (2006) · Neurosurgery · doi:10.1227/01.neu.0000197333.55473.ad · Cited by 133
Fingolimod and Sphingosine-1-Phosphate — Modifiers of Lymphocyte Migration
Maßberg, S., & von Andrian, U. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068159 · Cited by 129
Kahan, B. D., Karlix, J. L., Ferguson, R. M., Leichtman, A. B., Mulgaonkar, S. P., Gonwa, T. A., Skerjanec, A., Schmouder, R., & Chodoff, L. (2003) · Transplantation · doi:10.1097/01.tp.0000084822.01372.ac · Cited by 127
Lusardi, T. A., Wolf, J. A., Putt, M., Smith, D. H., & Meaney, D. F. (2004) · Journal of Neurotrauma · doi:10.1089/089771504772695959 · Cited by 115
Chronological changes of perihematomal edema of human intracerebral hematoma
Inaji, M., Tomita, H., Tone, O., et al. (2003) · Springer eBooks · doi:10.1007/978-3-7091-0651-8_91 · Cited by 104
Budde, K., Schmouder, R., Nashan, B., Brunkhorst, R. R., Lücker, P. W., Mayer, T., Brookman, L. J., Nedelman, J. R., Skerjanec, A., Böhler, T., et al. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00130.x · Cited by 102
Multiple‐Dose FTY720: Tolerability, Pharmacokinetics, and Lymphocyte Responses in Healthy Subjects
Kovarik, J. M., Schmouder, R., Barilla, D., Rivière, G., Wang, Y., & Hunt, T. L. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004264165 · Cited by 95
Campos, F., Qin, T., Castillo, J., Seo, J. H., Arai, K., Lo, E. H., & Waeber, C. (2013) · Stroke · doi:10.1161/strokeaha.112.679043 · Cited by 92
Magnus, T. U., Wiendl, H., & Kleinschnitz, C. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328352ede6 · Cited by 85
Hao, J., Campagnolo, D. I., Liu, R., Piao, W., Shi, S. X.-Y., Hu, B., Xiang, R., Zhou, Q., Vollmer, T. L., Kaer, L. V., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22339 · Cited by 78
Self-citationFingolimod exerts neuroprotective effects in a mouse model of intracerebral hemorrhage
Lü, L., Barfejani, A. H., Qin, T., Dong, Q., Ayata, C., & Waeber, C. (2014) · Brain Research · doi:10.1016/j.brainres.2014.01.048 · Cited by 73
FTY720 is Neuroprotective and Improves Functional Outcomes After Intracerebral Hemorrhage in Mice
Rolland, W. B., Manaenko, A., Lekic, T., Hasegawa, Y., Ostrowski, R. P., Tang, J., & Zhang, J. H. (2011) · Acta neurochirurgica. Supplementum · doi:10.1007/978-3-7091-0693-8_36 · Cited by 69
Matz, P. G., Lewén, A., & Chan, P. H. (2001) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200108000-00004 · Cited by 34
Cited by
Neuroinflammation, Stroke, Blood-Brain Barrier Dysfunction, and Imaging Modalities
Candelario-Jalil, E., Dijkhuizen, R. M., & Magnus, T. (2022) · Stroke · doi:10.1161/strokeaha.122.036946 · Cited by 953
Modulators of microglial activation and polarization after intracerebral haemorrhage
Lan, X., Han, X., Li, Q., Yang, Q.-W., & Wang, J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.69 · Cited by 915
Global brain inflammation in stroke
Shi, K., Tian, D.-C., Li, Z.-G., Ducruet, A. F., Lawton, M. T., & Shi, F.-D. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30078-x · Cited by 911
Self-citationImmune responses to stroke: mechanisms, modulation, and therapeutic potential.
Iadecola, C., Buckwalter, M. S., & Anrather, J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135530 · Cited by 853
Functions and mechanisms of microglia/macrophages in neuroinflammation and neurogenesis after stroke
Xiong, X.-Y., Liu, L., & Yang, Q.-W. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.05.001 · Cited by 701
Metadata
- Authors
- Fu, Y., Hao, J., Zhang, N., Ren, L., Sun, N., Li, Y.-J., Yan, Y., Huang, D., Yu, C., & Shi, F.-D.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2014-09-01
- Volume
- 71
- Issue
- 9
- Pages
- 1092
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W2164884787
- Cited by
- 278
- References
- 36
- FWCI
- 13.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.